There’s a lot to be optimistic about in the Healthcare sector as 1 analysts just weighed in on and Epizyme (EPZM) with bullish sentiments.
Epizyme (EPZM)
In a report issued on March 26, David Lebovitz from Morgan Stanley maintained a Buy rating on Epizyme, with a price target of $28.00. The company’s shares closed last Tuesday at $11.84, close to its 52-week low of $9.90.
According to TipRanks.com, Lebovitz is a 3-star analyst with an average return of 7.0% and a 56.0% success rate. Lebovitz covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals, Syndax Pharmaceuticals, and Ionis Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Epizyme with a $21.40 average price target, which is a 78.0% upside from current levels. In a report issued on March 18, Wedbush also reiterated a Buy rating on the stock with a $30.00 price target.
See today’s analyst top recommended stocks >>
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on EPZM:
